Physician profile
Haleh Stratton
NPI 1710125745
$8,062.00
in general payments reported to CMS, 2019-2025
26 companies · $2,038 in 2025
The $2,038 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,156 · 2022: $1,251 · 2023: $1,971 · 2024: $1,646 · 2025: $2,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,455 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,454.81 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,140.22 | 2021-2025 | |
| Incyte Corporation | $912.61 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $736.61 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $712.57 | 2021-2025 | Ilumya, Winlevi |
| Abbvie INC. | $699.29 | 2021-2025 | |
| Genzyme Corporation | $698.78 | 2021-2025 | |
| Lilly USA, LLC | $546.88 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $351.95 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $323.40 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $276.38 | 2023-2025 | Sotyktu |
| Vyne Pharmaceuticals INC. | $235.59 | 2021 | |
| Leo Pharma INC. | $224.49 | 2022-2025 | Adbry |
| Journey Medical Corporation | $162.67 | 2021-2025 | |
| Amgen INC. | $141.29 | 2023 | Otezla |
| Pfizer INC. | $137.29 | 2021-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $131.71 | 2021-2025 | |
| Dermavant Sciences, INC. | $125.64 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.21 | 2023-2024 | Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $105.27 | 2021-2024 | Jublia, Arazlo, Cabtreo |
| Ucb, INC. | $104.06 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $56.94 | 2023-2025 | Epsolay, Aklief |
| Nobelpharma America, LLC | $32.65 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $24.22 | 2023 | Valchlor |
| Fidia Pharma USA INC. | $23.96 | 2024 | |
| Organon LLC | $22.25 | 2025 | |
| Botanix Sb INC | $21.07 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haleh Stratton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.